US Radiotherapy Market

The report "US Radiotherapy Market by Technology (EBRT: MR LINAC, Stereotactic, Particle; IBRT/Brachytherapy, Cobalt-60 Teletherapy), Procedure (IGRT, IMRT, 3D-CRT, HDR, LDR, PDR), Cancer (Prostate, Breast, Lung, CRC), End User (Hospital, IRC) - Forecasts to 2030", is projected to reach USD 2.49 billion by 2030 from USD 3.25 billion in 2024, at a CAGR of 4.6%.

US Radiotherapy Market- Forecast to 2030. Browse over 176 tables, 62 figures, and an in-depth TOC on the US Radiotherapy market report. Early buyers will receive 10% customization on the report.

To know about the assumptions considered for the study download the pdf brochure

The US radiotherapy market is growing due to ongoing technological innovations and appetite for faster adoption of novel techniques such as increasing use of SBRT (Stereotactic Body Radiation Therapy) and IGRT (Image-Guided Radiation Therapy), the rising R&D investment for cancer research, growing adoption of AI-powered treatment planning for precise dose delivery, and expansion of medicare and medicaid coverage for advanced radiotherapy techniques. High capital investment and setup & maintenance costs for advanced radiotherapy equipment like proton therapy and MR-guided radiotherapy are major concerns for the widespread adoption of radiotherapy.

The system segment accounted for the largest share of the US radiotherapy market in 2025.

Radiotherapy market is sub-segmented into systems/hardware,  software, and services. In 2025, the system segment dominated the market with rising hardware sales driven by higher demand for innovative platforms across cancer care centers, favorable reimbursement policies, and the rising demand for non-invasive treatments.

By application, the EBRT segment is expected to register higher growth in the US radiotherapy market in 2025.

Based on application, the US Radiotherapy market is segmented into external beam radiotherapy (EBRT) applications and internal beam radiotherapy (IBRT) applications. The external beam radiotherapy (EBRT) applications segment is expected to register the highest growth rate during the forecast period due to the increasing demand for accurate, efficient, and increasing research activities to study the application and efficacy of EBRT for new cancer types. The growth of proton and carbon ion therapy in EBRT and expansion of outpatient EBRT centers, is fueling the demand for external beam radiotherapy (EBRT) applications.

External beam radiotherapy technologies accounted for the largest share of the US radiotherapy market in 2025.

By technology, the US radiotherapy market is segmented into external beam radiotherapy, and internal beam radiotherapy/brachytherapy technologies. In 2025, external beam radiotherapy technologies accounted for the largest share among end users because of a number of significant reasons. The technology is widely preferred over other therapeutic techniques, such as brachytherapy and systemic radiotherapy, due to its wide benefits, fewer side effects, and cost-effectiveness. According to research published in the Journal of Medical Imaging and Radiation Oncology, for localized cancer, EBRT has a cure rate of 95.5% for intermediate-risk prostate cancer and 91.3% for high-risk prostate cancer. Furthermore, techniques comprised under EBRT such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and image-guided radiation therapy (IGRT) have become more prevalent.

Prominent players in the Radiotherapy market include Siemens Healthineers GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA WORLDWIDE (Belgium), ViewRay Technologies, Inc (US), Perspective Therapeutics, Inc. (US), Hitachi High Tech Corporation (Japan), Carl Zeiss Meditec AG (Germany) and Koninklijke Philips N.V. (Netherlands).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/